SBI Biotech 
Welcome,         Profile    Billing    Logout  
 7 Products   39 Diseases  7 Products   5 Trials   418 News 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
daxdilimab (HZN-7734) / Amgen
2022-000831-21: A Phase 2 trial to evaluate the efficacy and safety of daxdilimab in participants with primary discoid lupus erythematosus.

Ongoing
2
99
Europe
daxdilimab, HZN-7734, Solution for injection
Horizon Therapeutics Ireland DAC, Horizon Therapeutics Ireland DAC
Discoid Lupus Erythematosus, Lupus skin disease, Diseases [C] - Immune System Diseases [C20]
 
 
RECAST SLE, NCT04925934 / 2020-005528-12: Study of VIB7734 for the Treatment of Moderate to Severely Active SLE

Completed
2
214
Europe, US, RoW
VIB7734, Daxdilimab, HZN-7734, Placebo
Amgen
Lupus Erythematosus, Systemic
05/23
06/23
HZNP-DAX-201, NCT05368103: Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata

Completed
2
30
Canada, US
Daxdilimab, HZN-7734
Amgen
Alopecia Areata
08/23
01/24
2022-000855-35: An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Daxdilimab (HZN-7734) in Subjects with Systemic Lupus Erythematosus

Not yet recruiting
2
156
Europe
Daxdilimab, HZN-7734, VIB7734, Solution for injection
Horizon Therapeutics Ireland DAC, Horizon Therapeutics Ireland DAC
Systemic Lupus Erythematosus (SLE), Systemic Lupus Erythematosus, Diseases [C] - Immune System Diseases [C20]
 
 
RECAST SLE OLE, NCT05430854 / 2022-000855-35: Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study

Terminated
2
155
Europe, US, RoW
Daxdilimab, HZN-7734
Amgen, Horizon Therapeutics Ireland DAC
Systemic Lupus Erythematosus
10/23
10/23
RECAST DLE, NCT05591222 / 2022-000831-21: Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus

Terminated
2
72
Europe, Canada, US, RoW
Placebo, Daxdilimab, HZN-7734
Amgen, Horizon Therapeutics Ireland DAC
Discoid Lupus Erythematosus
05/25
05/25
NCT05540665 / 2022-001377-31: Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

Terminated
2
19
Europe, US, RoW
Daxdilimab, Placebo (Normal Saline)
Amgen, Horizon Therapeutics Ireland DAC
Lupus Nephritis
01/24
01/24
NCT05669014: A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)

Active, not recruiting
2
12
Europe, US, RoW
Daxdilimab, HZN-7734, Placebo
Amgen
Idiopathic Inflammatory Myositis
03/25
10/25
Allex (actinidia arguta extract) / Helixmith, SBI Biotech
NCT06712615: Phase II Study of PG-102(MG12) Compared with Placebo in Obesity and Type 2 Diabetes

Recruiting
2
144
RoW
PG-102, Placebo
ProGen. Co., Ltd.
Type 2 Diabetes Mellitus (T2DM), Obesity Type 2 Diabetes Mellitus
03/25
06/25
NCT06309667: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of PG-102 (MG12) in Healthy Adult and Obesity Participants.

Completed
1
102
RoW
PG-102(MG12), Placebo
ProGen. Co., Ltd.
Healthy, Overweight
02/25
02/25
NCT06891287: An Early Phase Study of RT-114

Not yet recruiting
1
60
NA
RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity, PG-102, Placebo
RANI Therapeutics
Obesity
03/26
04/26
teprasiran (QPI-1002) / Novartis, SBI Biotech
7487: Phase 2 trial of QPI-1002 for AKI

Ongoing
2
0
RoW
QPI-1002 (I5NP)
Chronic Kidney Disease
 
 
KK4277 / Kyowa Kirin
NCT05411016: A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus

Recruiting
1
157
Japan, RoW
Placebo, KK4277
Kyowa Kirin Co., Ltd.
Healthy Volunteers, Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
12/24
12/25
GNKS356 / SBI Biotech
No trials found
QP-CO1 / SBI Biotech, Lepton Pharma
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
daxdilimab (HZN-7734) / Amgen
2022-000831-21: A Phase 2 trial to evaluate the efficacy and safety of daxdilimab in participants with primary discoid lupus erythematosus.

Ongoing
2
99
Europe
daxdilimab, HZN-7734, Solution for injection
Horizon Therapeutics Ireland DAC, Horizon Therapeutics Ireland DAC
Discoid Lupus Erythematosus, Lupus skin disease, Diseases [C] - Immune System Diseases [C20]
 
 
RECAST SLE, NCT04925934 / 2020-005528-12: Study of VIB7734 for the Treatment of Moderate to Severely Active SLE

Completed
2
214
Europe, US, RoW
VIB7734, Daxdilimab, HZN-7734, Placebo
Amgen
Lupus Erythematosus, Systemic
05/23
06/23
HZNP-DAX-201, NCT05368103: Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata

Completed
2
30
Canada, US
Daxdilimab, HZN-7734
Amgen
Alopecia Areata
08/23
01/24
2022-000855-35: An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Daxdilimab (HZN-7734) in Subjects with Systemic Lupus Erythematosus

Not yet recruiting
2
156
Europe
Daxdilimab, HZN-7734, VIB7734, Solution for injection
Horizon Therapeutics Ireland DAC, Horizon Therapeutics Ireland DAC
Systemic Lupus Erythematosus (SLE), Systemic Lupus Erythematosus, Diseases [C] - Immune System Diseases [C20]
 
 
RECAST SLE OLE, NCT05430854 / 2022-000855-35: Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study

Terminated
2
155
Europe, US, RoW
Daxdilimab, HZN-7734
Amgen, Horizon Therapeutics Ireland DAC
Systemic Lupus Erythematosus
10/23
10/23
RECAST DLE, NCT05591222 / 2022-000831-21: Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus

Terminated
2
72
Europe, Canada, US, RoW
Placebo, Daxdilimab, HZN-7734
Amgen, Horizon Therapeutics Ireland DAC
Discoid Lupus Erythematosus
05/25
05/25
NCT05540665 / 2022-001377-31: Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

Terminated
2
19
Europe, US, RoW
Daxdilimab, Placebo (Normal Saline)
Amgen, Horizon Therapeutics Ireland DAC
Lupus Nephritis
01/24
01/24
NCT05669014: A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)

Active, not recruiting
2
12
Europe, US, RoW
Daxdilimab, HZN-7734, Placebo
Amgen
Idiopathic Inflammatory Myositis
03/25
10/25
Allex (actinidia arguta extract) / Helixmith, SBI Biotech
NCT06712615: Phase II Study of PG-102(MG12) Compared with Placebo in Obesity and Type 2 Diabetes

Recruiting
2
144
RoW
PG-102, Placebo
ProGen. Co., Ltd.
Type 2 Diabetes Mellitus (T2DM), Obesity Type 2 Diabetes Mellitus
03/25
06/25
NCT06309667: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of PG-102 (MG12) in Healthy Adult and Obesity Participants.

Completed
1
102
RoW
PG-102(MG12), Placebo
ProGen. Co., Ltd.
Healthy, Overweight
02/25
02/25
NCT06891287: An Early Phase Study of RT-114

Not yet recruiting
1
60
NA
RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity, PG-102, Placebo
RANI Therapeutics
Obesity
03/26
04/26
teprasiran (QPI-1002) / Novartis, SBI Biotech
7487: Phase 2 trial of QPI-1002 for AKI

Ongoing
2
0
RoW
QPI-1002 (I5NP)
Chronic Kidney Disease
 
 
KK4277 / Kyowa Kirin
NCT05411016: A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus

Recruiting
1
157
Japan, RoW
Placebo, KK4277
Kyowa Kirin Co., Ltd.
Healthy Volunteers, Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
12/24
12/25
GNKS356 / SBI Biotech
No trials found
QP-CO1 / SBI Biotech, Lepton Pharma
No trials found

Download Options